Skip to content

The clinical study of TBI/BU conditioning regimen in autologous hematopoietic stem cell transplantation for T-cell Non-Hodgkin lymphoma

The clinical study of TBI/BU conditioning regimen in autologous hematopoietic stem cell transplantation for T-cell Non-Hodgkin lymphoma -------single center, single arm, open clinical study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017651
Enrollment
Unknown
Registered
2018-08-08
Start date
2017-07-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-cell Non-Hodgkin lymphoma

Interventions

Case series:TBI/BU

Sponsors

Henan Tumor hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: All the following entry criteria must be met before inclusion: 1. Aged 14 to 65 years old; 2. ECOG score 3. Definite pathological results, color ultrasound, CT or pet-ct, bone puncture and other results were diagnosed as T cell lymphoma, and the stages were defined; 4. Currently, there is no other effective treatment program for patients, or patients voluntarily choose autologous hematopoietic stem cell transplantation; 5. The main tissues and organs of the patients have good functions: (1) cardiac function: no heart disease or coronary heart disease, and the cardiac function of the patients is level 1-2 (appendix 2);(2) liver function: TBIL is no more than 3ULN, AST is no more than 2.5ULN, and ALT is no more than 2.5ULN;(3) renal function: Cr = 1.25ULN; 6. The peripheral superficial vein blood route is unobstructed, which can meet the needs of intravenous drip; 7. The patient agrees to participate in this clinical study and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have systemic active infections that require treatment; 2. Suffering from serious heart, liver, renal insufficiency and other diseases; 3. HIV infected patients; 4. Suffering from severe autoimmune diseases or immunodeficiency diseases; 5. Severe allergic constitution; 6. Severe mental disorders; 7. With history of other malignant tumors; 8. Have participated in or are currently participating in other clinical trial researchers in the past 3 months.

Design outcomes

Primary

MeasureTime frame
blood routine examination;biochemical criterion;electrocardiogram;Electrocardiogram color doppler;bone marrow puncture;CT;PET-CT;

Countries

China

Contacts

Public ContactZhou Jian

Cancer Hospital Affiliated to Zhengzhou University & Henan Cancer Hospital

zhoujiandoctor@163.com+86 13623822347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026